Komori
Other Disclosures4596Kubota Pharmaceutical Holdings Co.,Ltd.Pharmaceuticals

Report on the Exhibition of Our Product “Kubota Glass” at the UK’s Largest Optical and Eyewear Exhibition, “100% Optical 2026”

We exhibited our myopia-control AR device “Kubota Glass” at “100% Optical 2026,” an optical and eyewear exhibition held in London, UK. At the exhibition, we exchanged views with approximately 100 industry professionals and used the opportunity to consider future expansion in the European market.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
100
Approximately 100 people, including optometrists, optical professionals and business owners with whom we exchanged views
Wording
Conditional
How definitive the wording is.

Announced details

Kubota Glass®100% Optical 2026
Applicable field (uses covered by this announcement)
Myopia controlOphthalmologyEyewearOptometryOptics, eyewear and optometry
Launch date28 February 2026 to 2 March 2026 (exhibition period; actual)
What the company reported numerically
Quantitative Effects

Exchanged views with approximately 100 people

Location (as indicated in this announcement)

London, UK (ExCeL London)

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Announced details
ItemDetails
Names of Products / Services CoveredKubota Glass®, 100% Optical 2026
Launch date28 February 2026 to 2 March 2026 (exhibition period; actual)
Applicable areaMyopia control, Ophthalmology, Eyewear, Optometry, Optics, eyewear and optometry
LocationLondon, UK (ExCeL London)
Quantitative EffectsExchanged views with approximately 100 people
Items this document does not state (13)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleUsage historyImpact on Business PerformanceSource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

One of our initiatives aimed at raising product awareness in the European market and expanding opportunities for dialogue with industry professionals.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Report on the Exhibition of Our Product “Kubota Glass” at the UK’s Largest Optical and Eyewear Exhibition, “100% Optical 2026” | Kubota Pharmaceutical Holdings Co.,Ltd. (4596) timely disclosure | Komori